Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...

Medigene Reports Results of Annual General Meeting Shareholders approve all proposed resolutionsRe-election of two members of the Supervisory BoardReduction of share capital by consolidation of shares at a ratio of 2:1 approvedCreation of new...